Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
Elisabeth Mahase
Abstract
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports Elisabeth MahaseThe antiviral drug molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor outcomes, Merck Sharp and Dohme (MSD) has reported.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineEmergency medicineMedical emergencyIntensive care medicineVirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research